近日，海昇药业发布公告称，公司股东王小青计划通过集中竞价或大宗交易方式减持其所持公司股份，拟减持比例不超过公司总股本的1.8%。本次减持计划自公告披露之日起15个交易日之后的六个月内进行，减持原因为个人资金需求。王小青目前持有海昇药业约3.2%的股份，为公司重要股东之一。根据公告，此次减持将严格遵守相关法律法规及交易所规则，不会影响公司治理结构和持续经营能力。海昇药业强调，公司基本面稳健，生产经营正常，此次减持属股东个人行为，与公司运营状况无直接关联。市场分析人士指出，虽然股东减持可能在短期内对股价造成一定压力，但若公司业绩持续向好，长期影响有限。投资者应关注后续减持进展公告，并结合公司财报、行业前景等综合判断投资价值。海昇药业作为一家专注于医药研发与生产的高新技术企业，近年来在创新药和仿制药领域均有布局，未来成长性仍被部分机构看好。
Recently, Haisheng Pharmaceutical announced that shareholder Wang Xiaoqing plans to reduce his stake in the company by up to 1.8% of its total shares through centralized bidding or block trading. The proposed reduction will take place within six months starting 15 trading days after the announcement, driven by personal funding needs. Wang currently holds approximately 3.2% of Haisheng Pharmaceutical’s shares, making him one of the company’s significant shareholders.According to the announcement, the share reduction will strictly comply with relevant laws, regulations, and exchange rules, and will not affect the company’s governance structure or its ongoing operations. Haisheng Pharmaceutical emphasized that its fundamentals remain solid and business operations are normal, noting that this reduction is a personal decision by the shareholder and not directly related to the company’s performance. Market analysts suggest that while such a move may exert short-term downward pressure on the stock price, its long-term impact is likely limited if the company continues to deliver strong financial results.Investors are advised to monitor subsequent announcements regarding the progress of the share reduction and assess the company’s investment value in light of its financial reports and industry outlook. As a high-tech enterprise focused on pharmaceutical R&D and manufacturing, Haisheng Pharmaceutical has been actively expanding its portfolio in both innovative and generic drugs, and some institutions remain optimistic about its future growth potential.
原创文章，作者：admin，如若转载，请注明出处：https://ktez.cn/18308.html